We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

By LabMedica International staff writers
Posted on 23 Apr 2025

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. More...

Now, a new study uses DNA origami structures to selectively deliver fluorescent imaging agents to pancreatic cancer cells without affecting normal cells.

The research, conducted by scientists at the University of Illinois Urbana-Champaign (Champaign, IL, USA) and Purdue University (West Lafayette, IN, USA), revealed that DNA origami structures, which are engineered to carry packets of imaging dye, can selectively target human KRAS mutant cancer cells. These cells are present in approximately 95% of pancreatic cancer cases. DNA, being a long double-stranded molecule, is particularly suited for folding into nanoscale scaffolds capable of holding molecules—in this case, fluorescent dyes—at precise locations to form new, synthetic molecular structures.

In their experiments, the researchers created 3D models of pancreatic cancer using "tumoroids" and microfluidic systems that replicate the complex tumor microenvironment. These microfluidic tumor-stroma models were designed to reduce reliance on animal tissue and enhance the potential for translating these findings to human clinical applications. To test how effectively the DNA origami structures were taken up by cancerous tissues, the researchers applied the dye-packed DNA structures to the tumor models and monitored their movement using fluorescence imaging. They further tested the distribution of these DNA origami packets in a more biologically relevant environment by administering them to mice implanted with human pancreatic tumor tissue.

The team experimented with various DNA origami shapes, including tube-shaped and tile-shaped molecules. The results, published in the journal Advanced Science, showed that tube-shaped molecules measuring approximately 70 nanometers in length and 30 nanometers in diameter, as well as smaller versions about 6 nanometers in length and 30 nanometers in diameter, exhibited the highest uptake by pancreatic cancer tissue, without being absorbed by surrounding non-cancerous tissue. In contrast, larger tube-shaped molecules and all tile-shaped molecules showed less effective results. Looking ahead, the researchers plan to explore the use of DNA origami structures loaded with chemotherapy drugs for targeted delivery to cancer cells, further minimizing impact on normal cells.

“This research highlights not only the potential for more accurate cancer imaging, but also selective chemotherapy delivery, a significant advancement over current pancreatic ductal adenocarcinoma treatments,” said Bumsoo Han, a mechanical science and engineering professor at University of Illinois Urbana-Champaign. “The current process of cancerous tissue removal through surgical resection can be improved greatly by more accurate imaging of tumor margins.”


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.